Drugs / CD19/CD22 CAR-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05797948 | Jul 2022 → Jun 2024 | B-cell non-Hodgkin lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05797948 ↗ |
| Modality | Cell therapy | “CAR-T therapy with AZA + FC (Azacitidine +Fludarabine +Cyclophosphamide) conditioning regimen.” NCT05797948 ↗ |
| Route | Other | “dual-target CAR-T cells were reinfused” NCT05797948 ↗ |
| Target | CD19 | “Targets of CAR-T cells are tandem CD19/CD22.” NCT05797948 ↗ |
| Target | CD22 | “Targets of CAR-T cells are tandem CD19/CD22.” NCT05797948 ↗ |